Domain Invest

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Wednesday, 9 May 2007

Love That Dirty Water

Posted on 04:20 by Unknown
The may come as news to some folks but we Bostonians can be a bit parochial and self-centered. We like to think of our fair city as the origin of some pretty spectacular stuff. (Have you heard of the United States of America?< /Stephen Colbert voice>) And we wonder how people can ever get tired of hearing us yammer on about the Red Sox (We won a World Series you know. First time in 86 years.)












In All Our Glory (Writer not pictured)

So as the IN VIVO Blog's resident Massachusen VC-watcher, I’m of two minds when I hear that West Coast venture firms are opening Boston offices. First comes the understandable sense of validation—someone recognizes our place in the industry. Then comes the feeling that we’re somehow become an outpost for … egad … West Coast firms!

At a dinner a few years back, the managing partner of a VC firm, in explaining plans to open a Boston office, suggested Boston was an up-and-coming region that might be the next San Diego! The next San Diego? I always thought San Diego was the next Boston!

What’s driving this rant is the recent news that Skyline Ventures—a highly regarded Palo Alto firm—hired Stephen J. Hoffman, formerly of TVM, to head its East Cost office in Boston refreshed those conflicted feelings. Skyline joins Abingworth, Kleiner Perkins, Morgenthaler and 5AM as out-of-towners who opened Boston-area offices over the past few years.

Skyline founder John Freund says the hiring had more to do with Hoffman than with the East Coast or Boston. “We knew he’d fit in with our firm perfectly and he can’t move from Boston,” Freund says. “The more we thought about it the more we thought it would be an advantage to have an office in Boston. We’ve done a lot of investments in Boston over the last two years so having a presence on the ground would be an advantage.” Among the many attractions of Boston is an influx of pharmaceutical companies opening shop in the area (Merck and Novartis among the largest).

It’s great to have Skyline here in Boston. Same goes for Abingworth, Morgenthaler, 5AM and, of course, Kleiner Perkins (which technically didn’t open an office but did hire former Acambis CSO Tom Monath as a Boston-based partner). The more venture capital firms in Boston, the better off the biotech and medical device industries will be.

We’re lucky to have a strong core of venture firms like SV Life Sciences and Polaris Ventures. Still, it’s striking that the only new venture blood in town seems to come from branch offices. With the exception of Clarus Ventures, which broke off from MPM Capital, I can’t recall the start of any significant venture firms in the Boston area in the past few years. (Tell us if I’m missing someone.)

Still, wouldn't it be nice if Boston could be the home-base of a significant new venture firms, rather than an outpost?

Go Sox!
Email ThisBlogThis!Share to XShare to Facebook
Posted in venture capital | No comments
Newer Post Older Post Home
View mobile version

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Take the Money…or Let it Roll?
    In his talk introducing the top-10 most licensable oncology drugs at the Therapeutic Alliances conference last Friday, Ben Bonifant of Campb...
  • $80 million upfront? About Average
    So Synta’s PR firm were pushing today’s deal with GlaxoSmithKline at us as “one of the biggest product deals this year” and indeed “among t...
  • Beijing Boost for Japanese Encephalitis Vaccine
    China has been preparing feverishly for the Beijing Olympics for years to showcase its new world position and economic power. China's co...
  • Reporting on Exubera: an A-Buse
    Many analysts have questioned the potential of Pfizer’s inhaled insulin, Exubera . Nonetheless, it was more than surprising to see the comme...
  • The Best Defense Is a Good Offense, Or Something Like That
    Merck and Schering-Plough put out a release a few minutes ago responding to critics of ENHANCE and the trial results' fallout: WHITEHOU...
  • Public Confidence in Drug Safety: Solution is in "Plane" Sight
    Active surveillance and data mining are scary, right? It is common wisdom that these tools in the hands of academics, health plans and regul...
  • Addex Ups Dealmaking Ante
    Addex Pharma today took a step up the dealmaking ladder , partnering its pre-IND positive allosteric modulator ADX63365 and back-up compound...
  • Pfizer UK Gets “Closer to Customers”
    “Increased patient safety” drove Pfizer’s recent deal with UK wholesaler Alliance UniChem, according to the partners. But no one’s buying th...
  • Another Look at Asia
    As a small follow up to our post last week on Sofinnova Partners' hiring an Asia-focused professional, VentureWire Lifescience reported...
  • Deals of the Week: "King of Pain" Edition
    Admittedly, it's been a quiet week for biz dev in pharma land. The big news has been clinical. On the positive side, the diabetes triumv...

Categories

  • Abbott
  • activist shareholders
  • ADHD
  • advisory committees
  • alliances
  • Alnylam
  • Alzheimer's disease
  • Amgen
  • Andrew von Eschenbach
  • Andrew Witty
  • Astellas
  • AstraZeneca
  • Avandia
  • Avastin
  • Barack Obama
  • Barr
  • Bayer
  • Big Pharma
  • BIO
  • Biogen Idec
  • biologics
  • biosimilars
  • blogging
  • BMS
  • Boston Scientific
  • brand names
  • business development
  • business models
  • cancer vaccines
  • Carl Icahn
  • CBO
  • CDER
  • Celgene
  • Cephalon
  • China
  • clinical development
  • CMS
  • co-promotes
  • comparative effectiveness
  • conference
  • Congress
  • consumer genomics
  • corporate culture
  • corporate governance
  • corporate venture capital
  • CVS Caremark
  • Cytyc
  • David Kessler
  • deals of the week
  • debt financing
  • Diabetes
  • diagnostics
  • Dick Clark
  • drug approvals
  • drug delivery
  • drug discovery
  • drug eluting stents
  • Drug Pricing
  • drug safety
  • drug samples
  • DTC Advertising
  • e-health
  • Eisai
  • Elan
  • Eli Lilly
  • Emphasys
  • emphysema
  • Endo
  • epo
  • Euro-Biotech Forum
  • Exits
  • Exubera
  • FDA
  • FDA/CMS Summit
  • FDAAA
  • Film and TV
  • financing
  • FOBs
  • Forest Labs
  • Galvus
  • gene therapy
  • Genentech
  • General Electric
  • generics
  • Genzyme
  • Gleevec
  • Google
  • GSK
  • Guidant
  • haircuts
  • Happy Holidays
  • HCV
  • Headhunting
  • Health Care Reform
  • hedge funds
  • Henry Waxman
  • hGH
  • HHS
  • Hillary Clinton
  • Hologic
  • hostile takeovers
  • hypertension
  • ImClone
  • IMS Health
  • In vitro diagnostics
  • In3
  • India
  • insomnia
  • instrumentation
  • insulin
  • Inverness
  • IP
  • IPO
  • IPO pricing
  • Isis Pharmaceuticals
  • Israel
  • IT
  • JAMA
  • Januvia
  • Japan
  • John McCain
  • Johnson and Johnson
  • JP Morgan
  • LaMattina
  • lawsuits
  • layoffs
  • legislation
  • Life-Cycle Management
  • Lipitor
  • Lucentis
  • management succession
  • Mark McClellan
  • marketing
  • Martin Mackay
  • medical devices
  • Medicare
  • Medicare Part D
  • Medimmune
  • Medtech Insight
  • Medtronic
  • Merck
  • Merck-Serono
  • mergers and acquisitions
  • Michael McCaughan
  • Millennium
  • mmm beer
  • MRI
  • multiple sclerosis
  • music
  • nanotechnology
  • NEJM
  • new drug approvals
  • new funds
  • NICE
  • NicOx
  • NIH
  • Nobel Prize
  • Novartis
  • Novo Nordisk
  • Nycomed
  • off-label promotion
  • oncology
  • ophthalmology
  • Orthopedics
  • osteoporosis
  • OTC drugs
  • Out-Partnering
  • Oxycontin
  • pain
  • Part D
  • Patient Advocacy
  • PDUFA
  • personalized medicine
  • Pfizer
  • pharmacy benefits
  • PhRMA
  • politics
  • poll results
  • PR
  • prasugrel
  • Presidential Election
  • Press Release of the Week
  • Primary Care
  • private equity
  • Procter and Gamble
  • PSA
  • Purdue Pharma
  • rare diseases
  • reimbursement
  • research and development productivity
  • research and development strategies
  • reverse mergers
  • rimonabant
  • RiskMAP
  • RNAi
  • Roche
  • Roger Longman
  • royalties
  • sales forces
  • Sanofi-aventis
  • Schering-Plough
  • Science Matters
  • Sepracor
  • shameless self-promotion
  • share buybacks
  • Shire
  • Sirtris
  • Smith and Nephew
  • Solvay
  • SPACs
  • spec pharma
  • spin-outs
  • sports
  • Start-Up
  • statins
  • Steve Nissen
  • Stryker
  • Supreme Court
  • Takeda
  • Teva
  • Thanksgiving
  • The RPM Report
  • UCB
  • vaccines
  • Velcade
  • Ventana
  • venture capital
  • venture debt
  • Venture Round
  • Vertex
  • Vioxx
  • Vytorin
  • Wacky World of Generics
  • While You Were ...
  • Wyeth
  • Zetia
  • Zimmer
  • ZymoGenetics

Blog Archive

  • ►  2008 (76)
    • ►  February (25)
    • ►  January (51)
  • ▼  2007 (329)
    • ►  December (32)
    • ►  November (42)
    • ►  October (37)
    • ►  September (33)
    • ►  August (29)
    • ►  July (39)
    • ►  June (39)
    • ▼  May (43)
      • Talking of Sons-of-Drugs…
      • Genzyme Buys to Build in Oncology, Again
      • While You Were BBQing
      • Will Warburg Pincus Fight?
      • A Boon for Byetta?
      • Playing Through
      • Large Molecules: Antidote to a Toxic FDA
      • Coincidence? Hmmaybe.
      • The Euro-Next Biotech Bubble?
      • The BIO Perspective: It Out-PhRMA's PhRMA
      • Yeah, I guess it works, but how much does it cost?
      • No, no, no, no, no...
      • Wrong on Purdue Execs
      • Nissen goes meta on GSK; markets take back $13 bil...
      • Look for the Union Label
      • The Downsizing Opportunity: Pipeline on the Cheap?
      • Biosite in a Box
      • Welcome to the Pfincubator
      • A June Wedding for Bristol/Sanofi?
      • The Value of Re-Cycling: $87 million?
      • Can P&G Stomach the Risk Even When It's Reduced?
      • Congress Is Still Open to Drug Incentives
      • M&A: Gulf War
      • The Import of FDA to Biotechs, CEO Entourages and ...
      • Is it Time to Buy Amgen?
      • But what’s in it for me? Antibiotic incentives i...
      • $100 million and the price of drug discovery
      • BIO Security
      • Provenge, the Pazdur effect, and looking for a sil...
      • Third Rock's a Charm
      • Ouch. The Pain of Pain
      • Europe's Best-Kept Biotech Secret?
      • Bristol & Isis: Stop Making Sense
      • Lilly's Shadow Government
      • Love That Dirty Water
      • At Novartis, competing venture funds aim to avoid ...
      • Perkins' Pulmonx Raises Round
      • BSX's Big Bite
      • Denosumab: Outclast by Reclast?
      • IPO Cabal? Not Really.
      • GSK's War of Succession
      • Celtic and Novartis: Nic Fix
      • Locking the Sample Cabinet
    • ►  April (16)
    • ►  March (13)
    • ►  February (5)
    • ►  January (1)
  • ►  2006 (8)
    • ►  December (3)
    • ►  November (5)
Powered by Blogger.

About Me

Unknown
View my complete profile